Key result
Review details optimal antiplatelet strategies balancing ischemic and bleeding risks for post-PCI GI bleeding.
Why the study?
Gastrointestinal bleeding after PCI carries high morbidity and mortality, but there are inadequate evidence-based data regarding whether dual or single antiplatelet therapy is optimal and which specific agent to continue.
Does optimal antiplatelet therapy prevent ischemic events and bleeding in patients with coronary artery disease after gastrointestinal bleeding post-PCI?
Does optimal antiplatelet therapy prevent ischemic events and bleeding in patients with coronary artery disease after gastrointestinal bleeding post-PCI?
This review provides a summarized approach and rationale for managing antiplatelet therapy in patients who experience gastrointestinal bleeding after PCI, balancing ischemic and bleeding risks.
Answers are grounded in this paper and cite their sources.
Summarizes risk-balanced antiplatelet approaches after post-PCI GI bleeding; leaves open optimal strategies pending prospective trials.
Gastrointestinal bleeding after percutaneous coronary intervention (PCI) is a not too uncommon clinical situation and is associated with high morbidity and mortality. After initial treatment, a number of clinical decisions must be made weighing the risks of ischemic events and future bleeding. In particular, healthcare providers must carefully balance the effectiveness of antiplatelet therapy in the secondary prevention of coronary events, primarily future spontaneous myocardial infarction and stent thrombosis, against the risk of major, most commonly gastrointestinal bleeding. The first question is whether a dual antiplatelet therapy strategy is required or if a single antiplatelet agent will suffice. Then, if a single antiplatelet agent is adequate, which agent should be continued. Although there is some guidance to answer some of these questions, there are inadequate evidence-based data for others. Below, we review the various considerations and summarize our approach and rationale to manage patients who had gastrointestinal bleeding after PCI.
No takes yet. Share an insight, caveat, or question.
Pickett et al. (2021) conducted a review in Gastrointestinal bleeding after percutaneous coronary intervention. Antiplatelet therapy was evaluated. This review discusses the optimal antiplatelet strategy, weighing ischemic and bleeding risks, for managing patients who experience gastrointestinal bleeding after percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: